GPT and hypophosphatemia: On the contrary, more patients in the sorafenib group developed diarrhea (33% vs. 23%), palmar-plantar erythrodysesthesia (54% vs. 14%), alopecia (21% vs. 2%), increased AST (51% vs. 37%), increased ALT (34% vs. 28%), increased amylase (53% vs. 40%), increased lipase (64% vs. 46%), hypophosphatemia (71% vs. 29%), and low hemoglobin (49% vs. 41%).